Phase IV Trial,The Efficacy and Safety Study of Fuganlin Oral Liquid in Children With Acute Upper Respiratory Infection

Low-dose group of Fuganlin Oral Liquid:dosage from 5 to 10 ml;

High-dose group of Fuganlin Oral Liquid:dosage from 10 to 20 ml;

Treatment for 1 week.Patients who were recovered within 1 week can withdrawal at any time.

Research purpose:

• Evaluate the safety and efficacy of Fuganlin oral Liquid when expanding the designated indications(Qi deficiency wind-heat syndrome to wind-heat syndrome) .
• Explore the relationship between elevated white blood cells and efficacy, age and efficacy, dose and efficacy,While treating with Fuganlin oral Liquid in children with acute respiratory infection.
• Observe the antiviral and immunomodulatory effects of Fuganlin oral Liquid.
• Provide data to support the clinical medicine guidelines and labels amendment of Fuganlin oral Liquid.

Inclusion criteria

• Patients diagnosed as acute upper respiratory infection.
• Patients with acute upper respiratory infection diagnosed as Tradition Chinese Medicine syndrome qi deficiency wind-heat.
• Patients aged 1 to 12 years old.
• Parents or guardians agreed to participate this study and signed the informed consent.

Exclusion criteria

• Patients whose total numbers of white blood cells around above1.3ULN.
• Patients diagnosed as suppurative tonsillitis, otitis media, bronchitis and other airway.
• Patients allergic to the test drug.
• Serious cardiovascular, liver,kidney and other primary systemic diseases.
• Patients should not be included in group according to investigator's evaluation.